Reverso Therapeutics: Development and In Vivo Validation of Next-Generation Reversable Anticoagulants.

• Unité de recherche: INNOSUISSE
• Numéro de projet: 131.499 IP-LS
• Titre du projet anglais: Reverso Therapeutics: Development and In Vivo Validation of Next-Generation Reversable Anticoagulants.

Mots-clé (Anglais)

Life sciences, Pharmaceuticals

Résumé des résultats (Abstract) (Anglais)

Anticoagulants are life-saving drugs that prevent dangerous blood clots but carry a risk of bleeding. This project will de-risk the development of a new anticoagulant that can be instantly reversed with a simple antidote, making this therapy safer, especially for patients at high risk of bleeding.